PHARMA MEDICO ApS
CVR number: 28665741
Hans Hartvig Seedorffs Stræde 12 B, 8000 Aarhus C
www.pharmamedico.com
Income statement (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 13 726.08 | 10 686.79 | 21 547.85 | 30 054.42 | 26 192.94 |
| Employee benefit expenses | -7 022.65 | -7 482.41 | -9 008.60 | -7 802.10 | -7 993.34 |
| Other operating expenses | - 149.00 | ||||
| Total depreciation | - 467.47 | - 369.21 | - 449.51 | - 493.99 | - 982.25 |
| EBIT | 6 235.96 | 2 835.16 | 11 940.74 | 21 758.32 | 17 217.36 |
| Other financial income | 184.61 | 25.69 | 1 049.07 | 33.55 | 945.64 |
| Other financial expenses | -58.08 | - 348.14 | - 329.94 | - 769.08 | - 130.06 |
| Net income from associates (fin.) | -71.00 | -11.22 | |||
| Pre-tax profit | 6 291.49 | 2 501.49 | 12 659.87 | 21 022.80 | 18 032.95 |
| Income taxes | -1 530.88 | - 532.58 | -2 277.14 | -4 584.75 | -4 014.32 |
| Net earnings | 4 760.61 | 1 968.91 | 10 382.73 | 16 438.05 | 14 018.63 |
Assets (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Development expenditure | 4 267.66 | 9 932.59 | 11 515.78 | ||
| Intangible assets total | 4 267.66 | 9 932.59 | 11 515.78 | ||
| Buildings | 624.43 | 751.13 | 575.69 | 339.15 | |
| Machinery and equipment | 649.07 | 801.71 | 626.77 | 500.77 | 733.71 |
| Tangible assets total | 1 273.50 | 1 552.83 | 1 202.46 | 839.92 | 733.71 |
| Holdings in group member companies | 11.22 | ||||
| Investments total | 11.22 | ||||
| Long term receivables total | |||||
| Finished products/goods | 3 444.31 | 3 670.94 | 3 125.88 | 3 396.22 | 3 017.28 |
| Inventories total | 3 444.31 | 3 670.94 | 3 125.88 | 3 396.22 | 3 017.28 |
| Current trade debtors | 6 754.25 | 9 093.71 | 18 253.29 | 28 457.37 | 19 130.24 |
| Current amounts owed by group member comp. | 10 006.52 | 9 579.00 | 6 921.34 | 8 175.33 | 7 297.03 |
| Prepayments and accrued income | 170.85 | 1 191.56 | 731.74 | 833.45 | 826.63 |
| Current other receivables | 1 923.70 | 1 996.90 | 1 968.51 | 2 286.18 | 2 770.46 |
| Current deferred tax assets | 21.00 | 69.00 | |||
| Short term receivables total | 18 876.33 | 21 930.17 | 27 874.88 | 39 752.33 | 30 024.36 |
| Cash and bank deposits | 10 688.51 | 9 113.42 | 11 745.35 | 9 845.49 | 26 666.44 |
| Cash and cash equivalents | 10 688.51 | 9 113.42 | 11 745.35 | 9 845.49 | 26 666.44 |
| Balance sheet total (assets) | 34 293.87 | 36 267.36 | 48 216.23 | 63 766.55 | 71 957.57 |
Equity and liabilities (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 126.25 | 126.25 | 126.25 | 126.25 | 126.25 |
| Shares repurchased | 4 500.00 | 6 000.00 | |||
| Other reserves | 3 328.77 | 7 747.42 | 2 982.31 | ||
| Retained earnings | 22 334.32 | 27 094.93 | 21 235.06 | 27 199.15 | 36 402.30 |
| Profit of the financial year | 4 760.61 | 1 968.91 | 10 382.73 | 16 438.05 | 14 018.63 |
| Shareholders equity total | 27 221.18 | 29 190.09 | 39 572.81 | 51 510.86 | 59 529.49 |
| Provisions | 845.30 | 2 125.00 | 2 444.00 | ||
| Non-current deferred tax liabilities | 110.05 | 318.84 | |||
| Non-current liabilities total | 110.05 | 318.84 | |||
| Current loans from credit institutions | 294.94 | 158.76 | |||
| Advances received | 678.55 | ||||
| Current trade creditors | 4 134.99 | 5 119.29 | 5 631.50 | 6 060.36 | 4 939.93 |
| Current owed to participating | 227.42 | 33.51 | 4.80 | 34.57 | 25.83 |
| Short-term deferred tax liabilities | 1 287.66 | 580.59 | 708.84 | 2 465.15 | 2 922.05 |
| Other non-interest bearing current liabilities | 333.20 | 1 025.05 | 1 116.60 | 1 275.67 | 1 937.52 |
| Accruals and deferred income | 300.83 | 336.37 | |||
| Current liabilities total | 6 962.65 | 6 758.43 | 7 798.11 | 10 130.69 | 9 984.08 |
| Balance sheet total (liabilities) | 34 293.87 | 36 267.36 | 48 216.23 | 63 766.55 | 71 957.57 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.